Search Results - david+stein

3 Results Sort By:
Morpholino Oligomers to Prevent and Treat Coronavirus Infection
This technology licensing opportunity relates to antisense agents for treating or preventing a SARS-CoV-2 infection. The antisense agents are peptide-conjugated morpholino oligomers targeting pre-mRNA of a host (human) gene that encodes a protease. Some antisense agents included within the scope of this technology include agents previously shown to...
Published: 11/24/2020   |   Inventor(s): Hong Moulton, David Stein, Eva Bottcher-Friebershauser
Keywords(s):  
Category(s): Therapeutics
siRNA sequence and method for treating dengue virus infection
siRNA sequence and method for treating dengue virus infection OHSU Technology 1601 Value Proposition: Dengue virus (DENV) is a leading cause of illness in the tropics and subtropics, with as many as 100 million people infected yearly. Currently, there is no approved vaccine for DENV or any approved antiviral compositions to treat DENV either...
Published: 9/16/2020   |   Inventor(s): David Stein, Klaus Frueh, Stuart Perry, Sujan Shresta
Keywords(s): Research Tools - Reagents, Therapeutics - Infectious Diseases
Category(s): Therapeutics, Research Tools
Antisense Therapeutic Agents for Treatment of Covid-19
Technology Description This technology licensing opportunity relates to antisense agent compounds for treating or preventing a SARS-CoV-2 infection. A key feature of this technology is unique cell penetrating peptide and antisense oligomer (CPP-PMO) combinations that provide improved antiviral efficacy and reduced cytotoxicity. The compounds are oligomers...
Published: 9/9/2020   |   Inventor(s): David Stein, Hong Moulton, Kyle Rosenke, Heinrich Feldmann
Keywords(s): antisense, coronavirus, covid-19, Drug, SARS-CoV-2, Therapeutic
Category(s): Therapeutics
© 2021. All Rights Reserved. Powered by Inteum